BION

COM:BIONTECH

COM:BIONTECH

Add to Watchlist
  • Privately Held

Glancy Prongay & Murray LLP reminds investors of the March 12, 2024 deadline to file a lead plaintiff motion in a class action against BioNTech SE. The lawsuit pertains to investors who acquired BioNTech securities between March 30, 2022, and October 13, 2023. BioNTech's stock price fell due to missed financial estimates and inventory write-offs, leading to a class action alleging misleading statements about the company's business operations.

globenewswire.com

Pomerantz Law Firm has filed a class action lawsuit against BioNTech SE, a biotechnology company, alleging violations of federal securities laws during the period between March 30, 2022, and October 13, 2023. The lawsuit claims that BioNTech overstated demand for its COVID-19 vaccine, Comirnaty, and accumulated excess inventory, leading to significant losses for shareholders.

globenewswire.com

Rosen Law Firm reminds purchasers of BioNTech SE securities between March 30, 2022, and October 13, 2023, of the lead plaintiff deadline for a class action lawsuit. The lawsuit alleges that BioNTech made false statements regarding demand for Comirnaty, inventory write-offs, and commercial prospects, leading to investor damages.

globenewswire.com

Bragar Eagel & Squire, P.C., a shareholder rights law firm, reminds investors of class actions against BioNTech SE, Mobileye Global Inc., BioVie Inc., and Archer-Daniels-Midland Company. The actions allege false and misleading statements regarding the companies' businesses and operations.

globenewswire.com

Rosen Law Firm reminds BioNTech SE investors of the lead plaintiff deadline for securities purchased between March 30, 2022, and October 13, 2023. Investors may be entitled to compensation without out-of-pocket fees. The lawsuit alleges BioNTech made false statements regarding demand for Comirnaty, leading to potential damages for investors.

marketscreener.com